Updating results

388 results

Sort: Relevance | Date

Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Technology appraisal guidance In development

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]

In development [GID-TA10008] Expected publication date: TBC

Technology appraisal guidance In development

Generalised anxiety disorder - quetiapine [ID347]

In development [GID-TAG421] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Technology appraisal guidance In development

Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Technology appraisal guidance In development

Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

In development [GID-TA10018] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

In development [GID-TAG425] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

In development [GID-TAG424] Expected publication date: TBC

Technology appraisal guidance In development

Obesity - phentermine (with topiramate) [ID543]

In development [GID-TAG439] Expected publication date: TBC

Technology appraisal guidance In development

Constipation (opioid induced) - methylnaltrexone bromide [ID700]

In development [GID-TA10003] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell) - cetuximab [ID9]

In development [GID-TAG395] Expected publication date: TBC

Technology appraisal guidance In development

Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Technology appraisal guidance In development

Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

In development [GID-TAG440] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]

In development [GID-TAG444] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute) - serelaxin [ID673]

In development [GID-TAG454] Expected publication date: TBC

Technology appraisal guidance In development

Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

In development [GID-TA10144] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

In development [GID-TA10045] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]

In development [GID-TAG436] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Technology appraisal guidance In development

Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

In development [GID-TAG418] Expected publication date: TBC

Technology appraisal guidance In development

Mastocytosis (systemic) - masitinib [ID781]

In development [GID-TA10019] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Technology appraisal guidance In development

Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Technology appraisal guidance In development

Masitinib for treating amyotrophic lateral sclerosis [ID967]

In development [GID-TA10157] Expected publication date: TBC

Technology appraisal guidance In development

Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

In development [GID-TA10159] Expected publication date: TBC

Technology appraisal guidance In development

DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]

In development [GID-TA10143] Expected publication date: TBC

Technology appraisal guidance In development

Peramivir for treating influenza [ID828]

In development [GID-TA10155] Expected publication date: TBC

Technology appraisal guidance In development

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]

In development [GID-TAG405] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

In development [GID-TAG406] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

In development [GID-TA10148] Expected publication date: TBC

Technology appraisal guidance In development

Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Technology appraisal guidance In development

Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Technology appraisal guidance In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Technology appraisal guidance In development